Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in MRD+ or Relapsed Ph+ ALL
NCT04475731Phase 2Active, not recruiting
- Sponsor
- GIMEMA
- Start
- May 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by GIMEMA. Started May 2021; status: active, not recruiting.
02
Drugs
ponatinib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT04475731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04475731.